From: Diversity roles of CHD1L in normal cell function and tumorigenesis
Cancer | Deregulation | Downstream targets | Phenotypic effect | clinical impact | References |
---|---|---|---|---|---|
HCC | CHD1L↑ | P53↓, p21↓, cyclinE↑, CDK2↑ | G1/S phase transition↑, apoptosis↓, proliferation↑ |  | [1] |
CHD1L↑ | Nur77↓ | apoptosis↓ |  | [18] | |
CHD1L↑ | ARHGEF9↑, Cdc42↑ | migration↑, invasion↑, metastasis↑ |  | [14] | |
CHD1L↑ | TCTP↑, Cdc25c↓, Cdk1↓ | Mitotic progression↑, aneuploidy↑ |  | [15] | |
CHD1L↑ | SPOCK1↑, Akt↑ | apoptosis↓, invasion↑, metastasis↑ |  | [16] | |
 | CHD1L↑ | NTKL↑ | cell growth↑, colony formation↑, G1/S transition↑ |  | [17] |
 | CHD1L↑ | NA |  | Poor Prognosis | [21] |
Ovarian carcinoma | CHD1L↑ | NA | metastasis↑ | Prognostic biomarker | [23] |
 | CHD1L↑ | METAP2↑ | invasion↑, metastasis↑ |  | [19] |
Gastric cancer | CHD1L↑ | NA |  | Prognostic biomarker | [22] |
Colorectal carcinoma | CHD1L↑ | NA | G1/S phase transition↑, apoptosis↓ | Prognostic biomarker | [24] |
Bladder cancer | CHD1L↑ | NA |  | Prognostic biomarker | [25] |
Breast cancer | CHD1L↑ | NA |  | Prognostic biomarker | [27] |
CHD1L↑ | MDM2↑, p53↓ | Cell cycle↑, cell motility↑ |  | [63] | |
CHD1L↑ | PI3K↑, Akt↑, ARK5↑, mTOR↑, MMP2↑, MMP9↑ | chemotaxis↑, invasion↑, lung colonization↑ |  | [4] | |
Nasopharyageal carcinoma | CHD1L↑ | NA |  | Prognostic biomarker | [27] |
Glioma | CHD1L↑ | PCNA↑, β-catenin ↓, cyclinD1↑, p53↓, p21↓, cyclinE↑, Cdk2↑, c-capase3↓, Bcl2↑ | G1/S phase transition↑, proliferation↑, apoptosis↓, migration↑, invasion↑ |  | [64] |
NSCLC | CHD1L↑ | NA |  | Prognostic biomarker | [12] |
CHD1L↑ | ABCB1↑, c-Jun↑, NF-kB↑ | Cisplatin resistance |  | [66] | |
Myeloma | CHD1L↑ | c-capase9↓, capase3↓ | Anti-apoptosis, cell adhesion-mediated drug resistance↑ |  | [6] |
Pancreatic cancer | CHD1L↑ | β-catenin↑ | Cell proliferation↑ | Poor prognosis | [65] |
Esophageal carcinoma | CHD1L↑ | NA | proliferation↑, apoptosis↓, metastasis↑, invasion↑ | Poor prognosis | [28] |
 | CHD1L↑ | PI3K/Akt pathway↑ | viability↑, apoptosis↓, cisplatin cytotoxicity↓, glycolysis↑ |  | [67] |
Cholangiocarcinoma | CHD1L↑ | hMLH1↓ |  | Prognostic biomarker | [103] |
 | CHD1L↑ | P53↓, cyclinD1↑, CDK2↑, E-cadherin↓, N-cadherin↑, Vimentin↑ | EMT↑, G1/S transition↑, Cell proliferation↑ | Poor prognosis | [20] |